Casinos.com Announces International Casino Awards Winners
Voted entirely by players, the awards recognized standout casino venues worldwide and other areas of resorts, including the Best Casino Restaurant (Le Tren Bleu, Monte Carlo Casino), Best Casino Entertainer (Jamie Foxx), and even the industry's most luxurious restrooms in the form of the Royal Flush Awards (The Cosmopolitan, Las Vegas).
Results can be found here: casinos.com/international-casinos-day.
Bellagio Dominates the 2025 International Casino Awards
The Hippodrome Casino has been awarded the prestigious title of Best Casino in London. Meanwhile, the Grosvenor franchise demonstrated its nationwide appeal, with several of its venues earning top honours, including in Blackpool, Southend, Birmingham Hill Street, Swansea, Newcastle, Liverpool, and Brighton.
Taking center stage, Bellagio Resort & Casino in Las Vegas swept multiple top honors, including the coveted Best Casino in the World title.
'The Bellagio is iconic for a reason, and its recognition in four categories speaks volumes,' said Lee Gwilliam, SVP at Casinos.com. 'These awards were decided by players, people who have actually been inside these places, so every win is a true mark of excellence.'
In addition to being named the Best Casino in the World, the Bellagio also won awards for Best Casino in Las Vegas, Casino with the Best Staff, and Best Poker Room.
The awards coincided with the inaugural International Casinos Day, officially proclaimed by Las Vegas Mayor Shelley Berkley. Celebrated each year on May 15, this special date marks Las Vegas's 120th anniversary and serves as a global tribute to casino culture. It honors the vibrant entertainment experiences delivered by both land-based and online casinos, acknowledging their role in entertaining millions of people around the world.
'International Casinos Day gave the world a chance to recognize that casinos are about more than just gaming, they're entertainment hubs, cultural icons, and community landmarks,' Gwilliam added.
'It was refreshing to see casinos getting the credit they deserve. This celebration is just the beginning.'
Notable Award Winners in the UK
Best Casino In London - Hippodrome Casino
Best Casino In Blackpool - Grosvenor Casino Blackpool
Best Casino In Southend-on-Sea - Grosvenor Southend
Best Casino In Nottingham - Alea Casino
Best Casino In Birmingham - Grosvenor Casino Hill Street
Best Casino In Swansea - Grosvenor Casino Swansea
Best Casino In Cardiff - Les Croupiers Casino
Best Casino In Edinburgh - Genting Casino Edinburgh
Best Casino In Newcastle - Grosvenor Casino Newcastle
Best Casino In Glasgow - Genting Casino Glasgow
Best Casino In Liverpool - Grosvenor Casino Liverpool Leo
Best Casino In Brighton - Grosvenor Casino Brighton
Notable Winners in Europe
Best Casino In Ireland - Sporting Emporium
Best Casino In New Zealand - Christchurch Casino
Best Casino In Macau - Galaxy Macau
Best Casino In Italy - Casinò di Campione
Best Casino In Monaco - Casino de Monte-Carlo
Other Notable Award Winners
Best Riverboat Casino – Mississippi Belle II
Best Casino Cruise – Carnival Mardi Gras
Best Casino Restaurant – Le Tren Bleu
Best Family-Friendly Casino Resort – Circus Circus
Best Casino Rewards Program – MGM Rewards
Best Casino Staff – Bellagio Resort & Casino
Best New Casino Slot – Electric Joker
Best Poker Room – Bellagio Resort & Casino
Best Casino Influencer – Travel Ruby
Best Casino Entertainer – Jamie Foxx
Best Casino Show – The Mentalist
Casino With The Best Food Options – The Venetian
Best Smoke-Free Casino – Hard Rock Hotel Ottawa
Best Celebrity-Spotting Casino – Hard Rock Casino Tampa
The Most Luxurious Casino – MGM Grand
Best Casino Carpet – Caesars Palace
Best Land-Based Casino Slot – Wheel Of Fortune
The Most Romantic Casino – Casino Niagara
Best Casino For Hitting Jackpots – Hard Rock Casino Tampa
The Royal Flush Awards, Best Casino Toilets – The Cosmopolitan
About Casinos.com and Gambling.com Group
Casinos.com is a leading source for casino news, reviews, and rankings, serving players around the world. It is part of Gambling.com Group Limited (Nasdaq: GAMB), a publicly traded company that operates more than 50 websites dedicated to helping consumers navigate regulated gambling markets.
Gambling.com Group provides trusted resources for bettors and players through editorial content, rankings, product comparisons, and expert insights, with a mission to support safe and informed entertainment.
This press release may contain forward-looking statements, including projections or expectations related to the International Casino Awards and Casinos.com. Actual results may differ materially due to various risks and uncertainties. For more information, visit Gambling.com/corporate.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
4 minutes ago
- Associated Press
2 Day Pharmaceutical, Biopharmaceutical, Biologics and Medical Device FDA Inspection Preparedness and Compliance Seminar (ONLINE EVENT: September 3-4, 2025)
DUBLIN--(BUSINESS WIRE)--Aug 4, 2025-- The 'FDA Inspection Preparedness and Compliance' training has been added to offering. This is a practical, hands-on two-day seminar designed to provide pharmaceutical, biopharmaceutical, biologics and medical device professionals with the information and tools they require to prepare for and manage an FDA inspection efficiently, effectively and successfully. Many regulated companies preparing for FDA inspections are not prepared and the outcome can be negative as we see all the time with enforcement actions. This seminar provides the fundamentals and the ground rules on how to prepare for and survive an FDA inspection no matter if you are a Class I, II, III device or a pharmaceutical or biologics manufacturer. This presentation will review and emphasize the do's and don'ts and cardinal rules as to interviewing, how to respond, reviewing documentation, etiquette, use of certain words, body language, responding to questions/requests, etc., and certainly replying to 483's and Warning Letters. The course will go through what typically goes on during an FDA Inspection and will then cover how to prepare for, host and follow up to a regulatory inspection. It will emphasize and focus on the critical and vital elements that you should do or not do during the inspection. Typically, FDA inspections can be highly structured and there are procedures that are to be followed as you prepare for state of readiness. It is important for anyone who might be involved in the inspection to be aware of these procedures, including all employees and personnel to ensure there are no surprises. The course will also provide information for inspections conducted by international agencies as well as non-FDA agencies, including self-inspections for manufacturing and the famous FDA Mock Inspection or Mock Audit. It will explain how to prepare for an inspection, how to handle a scheduled or non-scheduled inspection, what to expect during an inspection and what follow up to expect after an inspection. Who Should Attend: This seminar will provide an overview and in-depth snapshot of the entire process for preparing for and managing and FDA inspection and external regulatory inspections and for those companies who must establish proven and sustainable GXP Compliance Strategies and risk mitigation strategies when responding to a crisis. Employees who will benefit include all levels of management and departmental representatives from key functional areas and those who desire a better understanding or a 'refresh' overview of the FDA inspection process from preparing for the inspections, during the inspections and post-inspection responsibilities and follow up activities with FDA, including: This live training Seminar includes the following for each registered attendee: Key Topics Covered: Day 1 Day 2 Recap of Day 1 and Day 2 Exercise on Day 2 Debrief/Adjourn/Wrap-Up Speakers: Kelly Thomas Vice President Stallergenes Greer Ms. Thomas has over two decades of cGMP hands-on industry experience in both pharmaceutical and medical device manufacturing operations. Her experience covers all Quality Systems; as well as, all areas of validation; including, process/product validation, facilities validation, CSV and 21 CFR Part 11, test method validation, equipment/automated processes and cleaning validation. Utilizing strategic thinking, risk based approaches, and Lean principles, she has demonstrated success in steering and managing complex projects within the pharmaceutical and medical device industries. For more information about this training visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. View source version on CONTACT: Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDUSTRY KEYWORD: EDUCATION MEDICAL DEVICES HEALTH PHARMACEUTICAL TRAINING BIOTECHNOLOGY SOURCE: Research and Markets Copyright Business Wire 2025. PUB: 08/04/2025 08:41 AM/DISC: 08/04/2025 08:41 AM
Business Wire
5 minutes ago
- Business Wire
Rand Capital Reports Second Quarter 2025 Results
BUFFALO, N.Y.--(BUSINESS WIRE)-- Rand Capital Corporation (Nasdaq: RAND) ('Rand' or the 'Company'), a business development company providing alternative financing for lower middle market companies, announced its results for the second quarter ended June 30, 2025. 'We delivered net investment income growth in the second quarter, primarily benefiting from a non-cash capital gains incentive fee reversal tied to the write-down of our investment in Tilson,' said Daniel P. Penberthy, President and Chief Executive Officer of Rand. 'At the same time, total investment income declined due to the continued impact of portfolio loan repayments that have not yet been offset by new investments. Investment activity remains slower than desired amid ongoing economic uncertainty, which has led more borrowers to pay interest 'in kind' (PIK) by increasing their loan balances rather than using cash during the first half of 2025. As a result, over $1.2 million of interest was added to the principal of our portfolio obligations, representing approximately 34% of our total investment income.' Mr. Penberthy added, 'We are starting to see early signs of market improvement, which could return portions of our portfolio to current pay status and lead to stronger deal origination and execution. With approximately $25 million in total liquidity and no debt outstanding, we believe we are well-positioned to support our dividend and act quickly on new investment opportunities as conditions evolve.' Second Quarter Highlights (compared with the prior-year period unless otherwise noted) Total investment income was $1.6 million, a decrease of $534,000, or 25%, compared with the same period last year. The change was primarily driven by a 24% reduction in interest income from portfolio companies, reflecting the repayment of five debt instruments over the past year. Lower dividend income also contributed to the year-over-year decrease. Total expenses were a benefit of $864,000 compared with an expense of $2.7 million in the same period last year. This improvement was primarily driven by a $3.1 million reduction in capital gains incentive fee expense. In the second quarter of 2025, Rand recorded a $1.5 million capital gains incentive fee benefit, reflecting a net increase in unrealized depreciation, whereas the prior-year period included a $1.6 million expense. Additionally, lower average outstanding debt balances led to a $368,000 reduction in interest expense, and base management fees declined by $105,000 due to portfolio company principal repayments and valuation adjustments. Adjusted expenses, which exclude capital gains incentive fees, and is a non-GAAP financial measure, were $626,000 compared with $1.0 million in the second quarter of 2024. See the attached description of this non-GAAP financial measure and reconciliation table for adjusted expenses. Net investment income increased to $2.5 million, or $0.83 per share, compared with a loss of $517,000, or $0.20 per share, in the second quarter of 2024. Adjusted net investment income per share, a non-GAAP financial measure, which excludes the capital gains incentive fee, was $0.33 per share, compared with $0.44 per share in last year's second quarter. The second quarter of 2025 per share amounts were computed using 2,969,814 weighted average shares outstanding, reflecting a higher number of shares outstanding following the fourth quarter 2024 dividend, distributed in the first quarter of 2025, that was paid in part using shares of common stock. This compared with 2,581,021 weighted average shares outstanding for the second quarter of 2024. See the attached description of this non-GAAP financial measure and reconciliation table for adjusted net investment income per share. Portfolio and Investment Activity As of June 30, 2025, Rand's portfolio included investments with a fair value of $52.4 million across 19 portfolio businesses. This was a decrease of $18.5 million, or 26%, from December 31, 2024, primarily due to portfolio company loan repayments and valuation adjustments in multiple portfolio companies. The portfolio was comprised of approximately 86% debt investments and 14% equity investments at June 30, 2025. The annualized weighted average yield of debt investments, which includes PIK interest, was 12.2% at June 30, 2025, compared with 13.8% at the end of 2024. Second Quarter 2025: Funded a follow-on equity investment of $35,000 in Carolina Skiff LLC. Rand's total equity investment in Carolina Skiff had a fair value of $800,000 at quarter-end. The valuation of Rand's investment in Tilson Technologies decreased $9.5 million after it filed a voluntary petition for relief under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court, District of Delaware. Additional information regarding the Tilson Technologies bankruptcy can be found in Rand's Current Report on Form 8-K filed on May 30, 2025. Liquidity and Capital Resources Rand ended the quarter with $4.4 million in cash, an increase from $835,000 at year-end 2024. As of June 30, 2025, there was no outstanding balance on the Company's senior secured revolving credit facility. Mr. Penberthy stated, 'While the borrowing base formula provided approximately $20 million of unused availability as of June 30, 2025, we have the capacity to increase this to a total of $25 million, subject to certain borrowing criteria and portfolio eligibility requirements through its 2027 maturity.' The Company did not repurchase any outstanding common stock during the second quarter of 2025. Dividends On April 30, 2025, Rand declared its regular quarterly cash dividend of $0.29 per share, which was paid during the second quarter to shareholders of record as of May 30, 2025. On July 28, 2025, Rand declared its regular quarterly cash dividend of $0.29 per share. The cash dividend will be distributed on or about September 12, 2025, to shareholders of record as of August 29, 2025. Webcast and Conference Call Rand will host a conference call and webcast on Monday, August 4, 2025, at 1:30 p.m. Eastern Time, to review its financial results. The review will be accompanied by a slide presentation, which will be available on Rand's website at in the 'Investor Relations' section. Rand's conference call can be accessed by calling (201) 689-8263. Alternatively, the webcast can be monitored on Rand's website at under 'Investors' where the replay will also be available. A telephonic replay will be available from 5:30 p.m. ET on the day of the call through Monday, August 18, 2025. To listen to the archived call, dial (412) 317-6671 and enter replay pin 13754384. A transcript of the call will also be posted once available. ABOUT RAND CAPITAL Rand Capital Corporation (Nasdaq: RAND) is an externally managed business development company (BDC). The Company's investment objective is to maximize total return to its shareholders with current income and capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. Rand primarily invests in businesses that have sustainable, differentiated and market-proven products, revenue of more than $10 million and EBITDA in excess of $1.5 million. The Company's investment activities are managed by its external investment adviser, Rand Capital Management, LLC. Additional information can be found at the Company's website where it regularly posts information: Safe Harbor Statement This press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than historical facts, including but not limited to statements regarding the strategy of the Company and its outlook; statements regarding the implementation of the Company's strategy and the growth of its dividend; statements regarding the impact of market improvements on returning portions of the debt portfolio to current pay status; and any assumptions underlying any of the foregoing, are forward-looking statements. Forward-looking statements concern future circumstances and results and other statements that are not historical facts and are sometimes identified by the words 'may,' 'will,' 'should,' 'potential,' 'intend,' 'expect,' 'endeavor,' 'seek,' 'anticipate,' 'estimate,' 'overestimate,' 'underestimate,' 'believe,' 'could,' 'project,' 'predict,' 'continue,' 'target' or other similar words or expressions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove to be incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. The inclusion of such statements should not be regarded as a representation that such plans, estimates or expectations will be achieved. Important factors that could cause actual results to differ materially from such plans, estimates or expectations include, among others, (1) evolving legal, regulatory and tax regimes; (2) changes in general economic and/or industry specific conditions; and (3) other risk factors as detailed from time to time in Rand's reports filed with the Securities and Exchange Commission ('SEC'), including Rand's annual report on Form 10-K for the year ended December 31, 2024, quarterly reports on Form 10-Q, and other documents filed with the SEC. Consequently, such forward-looking statements should be regarded as Rand's current plans, estimates and beliefs. Except as required by applicable law, Rand assumes no obligation to update the forward-looking information contained in this release. FINANCIAL TABLES FOLLOW Rand Capital Corporation and Subsidiaries June 30, 2 025 (Unaudited) 2 024 ASSETS Investments at fair value: Control investments (cost of $6,563,940 and $6,188,940, respectively) $ 2,000,000 $ 2,500,000 Affiliate investments (cost of $44,800,334 and $42,488,804, respectively) 42,717,475 51,668,144 Non-Control/Non-Affiliate investments (cost of $9,912,772 and $19,442,491, respectively) 7,646,779 16,649,897 52,364,254 70,818,041 Cash 4,419,813 834,805 Interest receivable (net of allowance of $25,337 and $0, respectively) 250,263 357,530 Prepaid income taxes 344,695 329,365 Deferred tax asset, net 111,438 2,161 Other assets 149,076 115,531 Total assets $ 57,639,539 $ 72,457,433 LIABILITIES AND STOCKHOLDERS' EQUITY (NET ASSETS) Liabilities: Due to investment adviser $ 509,500 $ 2,182,846 Accounts payable and accrued expenses 38,600 92,568 Line of credit — 600,000 Capital gains incentive fees — 1,565,000 Deferred revenue 377,485 516,441 Dividend payable — 2,168,058 Total liabilities 925,585 7,124,913 Stockholders' equity (net assets): Common stock, $0.10 par; shares authorized 100,000,000; shares issued: 3,037,709 at 6/30/25 and 2,648,916 at 12/31/24; shares outstanding: 2,969,814 at 6/30/25 and 2,581,021 at 12/31/24 303,771 264,892 Capital in excess of par value 64,051,504 55,419,620 Stock dividends distributable: 0 shares at 6/30/25 and 388,793 shares at 12/31/24 — 8,672,231 Treasury stock, at cost: 67,895 shares at 6/30/25 and 12/31/24 (1,566,605 ) (1,566,605 ) Total distributable earnings (6,074,716 ) 2,542,382 Total stockholders' equity (net assets) (per share – 6/30/25: $19.10; 12/31/24: $25.31) 56,713,954 65,332,520 Total liabilities and stockholders' equity (net assets) $ 57,639,539 $ 72,457,433 Expand Rand Capital Corporation and Subsidiaries Consolidated Statements of Operations (Unaudited) Investment income: Interest from portfolio companies: Control investments $ 12,979 $ 198,885 $ 12,979 $ 386,368 Affiliate investments 1,264,789 1,192,116 2,547,648 2,358,201 Non-Control/Non-Affiliate investments 236,794 604,226 631,101 1,064,306 Total interest from portfolio companies 1,514,562 1,995,227 3,191,728 3,808,875 Interest from other investments: Non-Control/Non-Affiliate investments 36,556 144 46,939 2,058 Total interest from other investments 36,556 144 46,939 2,058 Dividend and other investment income: Affiliate investments — 13,125 13,125 26,250 Non-Control/Non-Affiliate investments — 60,050 — 198,760 Total dividend and other investment income — 73,175 13,125 225,010 Fee income: Control investments 4,516 4,516 9,032 9,032 Affiliate investments 42,891 54,815 174,646 128,535 Non-Control/Non-Affiliate investments 3,772 8,272 174,731 29,858 Total fee income 51,179 67,603 358,409 167,425 Total investment income 1,602,297 2,136,149 3,610,201 4,203,368 Expenses: Base management fee 217,649 322,672 469,857 625,267 Income based incentive fees — — 119,673 — Capital gains incentive fees (1,490,000 ) 1,641,000 (1,565,000 ) 1,753,300 Interest expense 25,417 393,172 61,903 783,192 Professional fees 142,020 91,460 350,862 323,767 Stockholders and office operating 103,349 82,667 194,112 151,695 Directors' fees 66,550 66,550 130,400 130,400 Administrative fees 50,250 40,000 99,000 78,167 Insurance 9,974 10,380 23,136 23,424 Corporate development (2,493 ) 4,881 4,501 10,426 Bad debt expense 13,125 — 38,462 — Total (benefits) expenses (864,159 ) 2,652,782 (73,094 ) 3,879,638 Net investment income (loss) before income taxes: 2,466,456 (516,633 ) 3,683,295 323,730 Income tax (benefit) expense (11,778 ) 562 (13,054 ) 1,340 Net investment income (loss) 2,478,234 (517,195 ) 3,696,349 322,390 Net realized gain (loss) on sales and dispositions of investments: Affiliate investments — (831,891 ) 925,357 (831,891 ) Non-Control/Non-Affiliate investments — 1,259,999 (25 ) 4,710,091 Net realized gain (loss) on sales and dispositions of investments — 428,108 925,332 3,878,200 Net change in unrealized appreciation/depreciation on investments: Control investments — — (875,000 ) — Affiliate investments (10,122,270 ) 8,849,945 (10,545,654 ) 8,749,945 Non-Control/Non-Affiliate investments (189,944 ) (1,070,919 ) (189,944 ) (3,861,215 ) Change in unrealized appreciation/depreciation before income taxes (10,312,214 ) 7,779,026 (11,610,598 ) 4,888,730 Deferred income tax benefit (97,826 ) (47,834 ) (94,210 ) (47,834 ) Net change in unrealized appreciation/depreciation on investments (10,214,388 ) 7,826,860 (11,516,388 ) 4,936,564 Net realized and unrealized (loss) gain on investments (10,214,388 ) 8,254,968 (10,591,056 ) 8,814,764 Net (decrease) increase in net assets from operations $ (7,736,154 ) $ 7,737,773 $ (6,894,707 ) $ 9,137,154 Weighted average shares outstanding 2,969,814 2,581,021 2,920,135 2,581,021 Basic and diluted net (decrease) increase in net assets from operations per share $ (2.60 ) $ 3.00 $ (2.36 ) $ 3.54 Expand Rand Capital Corporation and Subsidiaries Consolidated Statements of Changes in Net Assets (Unaudited) Three months ended June 30, 2025 Three months ended June 30, 2024 Six months ended June 30, 2025 Six months ended June 30, 2024 Net assets at beginning of period $ 65,311,253 $ 61,569,339 $ 65,332,520 $ 60,815,213 Net investment income (loss) 2,478,234 (517,195 ) 3,696,349 322,390 Net realized gain on sales and dispositions of investments — 428,108 925,332 3,878,200 Net change in unrealized appreciation/depreciation on investments (10,214,388 ) 7,826,860 (11,516,388 ) 4,936,564 Net (decrease) increase in net assets from operations (7,736,154 ) 7,737,773 (6,894,707 ) 9,137,154 Declaration of dividend (861,145 ) (748,496 ) (1,723,859 ) (1,393,751 ) Net assets at end of period $ 56,713,954 $ 68,558,616 $ 56,713,954 $ 68,558,616 Expand Rand Capital Corporation and Subsidiaries Reconciliation of GAAP Total Expense to Non-GAAP Adjusted Expenses (Unaudited) In addition to reporting total expenses, which is a U.S. generally accepted accounting principle ('GAAP') financial measure, Rand presents adjusted expenses, which is a non-GAAP financial measure. Adjusted expenses is defined as GAAP total expenses removing the effect of any (credits)/expenses for capital gains incentive fees accrual. GAAP total expenses is the most directly comparable GAAP financial measure. Rand believes that adjusted expenses provides useful information to investors regarding financial performance because it is a method the Company uses to measure its financial and business trends related to its results of operations. The presentation of this additional information is not meant to be considered in isolation or as a substitute for financial results prepared in accordance with GAAP. Reconciliation of GAAP Net Investment Income (Loss) per Share to Adjusted Net Investment Income per Share (Unaudited) In addition to reporting Net Investment Income (Loss) per Share, which is a GAAP financial measure, the Company presents Adjusted Net Investment Income per Share, which is a non-GAAP financial measure. Adjusted Net Investment Income per Share is defined as GAAP Net Investment Income per Share removing the effect of any (credits)/expenses for capital gains incentive fees. GAAP Net Investment Income per Share is the most directly comparable GAAP financial measure. Rand believes that Adjusted Net Investment Income per Share provides useful information to investors regarding financial performance because it is a method the Company uses to measure its financial and business trends related to its results of operations. The presentation of this additional information is not meant to be considered in isolation or as a substitute for financial results prepared in accordance with GAAP. The per share amounts for the three and six months ended June 30, 2025 were computed using 2,969,814 and 2,920,135 weighted average shares outstanding, respectively, reflecting a higher number of shares outstanding following the fourth quarter 2024 dividend, which was paid in part using shares of common stock. This compared with 2,581,021 weighted average shares outstanding for the three and six months ended June 30, 2024.
Business Wire
5 minutes ago
- Business Wire
Alpha Cognition to Report Second Quarter 2025 Financial Results and Operating Overview
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will release financial results for the second quarter on August 14, 2025 after close of market. Following the release, management will host a conference call to review financial and operating results. Conference Call Information: To participate in the conference call, please use the dial-in information below: Participant Listening: 1-877-407-9039 or 1-201-689-8470 or - Participants can use Guest dial-in #s above and be answered by an operator OR click the Call me™ link for instant telephone access to the event. Call me™ link will be made active 15 minutes prior to scheduled start time. The live audio webcast will be accessible here: A replay of the earnings call is available after the conference call has ended. Replay Dial-In: 1-844-512-2921 or 1-412-317-6671 Access ID: 13754595 Replay webcast: About Alpha Cognition Inc. Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury ('mTBI'), for which there are currently no approved treatment options. ZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ZUNVEYL's active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer's dementia, and as an intranasal formulation for Cognitive Impairment with mTBI.] Forward-looking Statements This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company's current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward‐looking statements by the words 'may,' 'might,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'intend,' 'plan,' 'objective,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'target,' 'seek,' 'contemplate,' 'continue' and 'ongoing,' or the negative of these terms, or other comparable terminology intended to identify statements about the future. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward-looking statements are subject to certain risks, including risks regarding our ability to raise sufficient capital to implement our plans to commercialize ZUNVEYL, risks regarding the efficacy and tolerability of ZUNVEYL, risks related to ongoing regulatory oversight on the safety of ZUNVEYL, risk related to market adoption of ZUNVEYL, risks related to the Company's intellectual property in relation to ZUNVEYL, risks related to the commercial manufacturing, distribution, marketing and sale of ZUNVEYL, risks related to product liability and other risks as described in the Company's filings with Canadian securities regulatory authorities and available at and the Company's filings with the United States Securities and Exchange Commission (the 'SEC'), including those risk factors under the heading 'Risk Factors' in the Company's [ Form S-1/A registration statement as filed with the SEC on November 6, 2024 and available at ] These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future, except as required by law.
